What are the high‑level management guidelines for primary varicella infection and herpes zoster?

High-Level Management of Varicella Zoster Virus Infections

The most effective strategy to prevent both primary varicella infection and herpes zoster is vaccination, with treatment decisions for active infections based on patient age, immune status, and disease severity. 1

Primary Varicella (Chickenpox) Management

Prevention

• Vaccination is the cornerstone of prevention using live-attenuated Oka strain VZV vaccines licensed for individuals ≥12 months of age 1
• A routine 2-dose varicella immunization schedule provides optimal protection in children 1
• Post-exposure prophylaxis with oral acyclovir may be considered when immunoglobulin cannot be administered and vaccination is too late 2

Treatment of Active Varicella

Oral acyclovir treatment is recommended for:

• All children over 12 years of age with primary varicella 2
• Younger children at risk of severe varicella (immunocompromised, chronic disease, atopic dermatitis on steroids) 2, 3
• Adolescents and young adults with infection 4
• Pregnant patients to prevent complications 3

Intravenous acyclovir is mandatory for:

• Patients with immune deficiencies 2
• Newborns with varicella 2
• Complicated cases including neurological involvement 2
• Life-threatening infections in immunocompromised patients (AIDS, transplant recipients, cancer patients) 5

Clinical Recognition

• After 14-16 day incubation (range 10-21 days), characteristic vesicular rash appears in varying stages (macules→papules→vesicles→pustules→scabs) 1
• Rash concentrates on trunk and head more than extremities, with 250-500 lesions typical in wild-type disease 1
• Patient is contagious from 1-2 days before rash onset until all lesions are crusted 1

Herpes Zoster (Shingles) Management

Prevention

• Two vaccines are approved: live-attenuated zoster vaccine and recombinant zoster vaccine (RZV) 1
• Vaccination reduces risk of herpes zoster and postherpetic neuralgia 1
• The recombinant HZ vaccine shows stronger and more durable protection, with multiple doses providing greater dementia risk reduction than single dose 6
• Risk-adapted pharmacological prophylaxis should be implemented for high-risk malignancy patients 7

Treatment of Active Herpes Zoster

Oral acyclovir (800 mg five times daily for 10 days) is beneficial for:

• Otherwise healthy patients with rash in locations other than the trunk 2
• Patients over 50 years of age to accelerate cutaneous healing 2, 4
• Immunocompetent patients to reduce postherpetic neuralgia risk 4

Intravenous acyclovir is the treatment of choice for:

• Immunocompromised patients with herpes zoster 1, 2
• Complicated cases including neurological involvement 2
• Herpes zoster ophthalmicus requiring aggressive treatment 1

Special Considerations for Herpes Zoster

• Approximately 20-30% of people develop herpes zoster over their lifetime, with incidence increasing markedly after age 50 1
• Recurrent HZ episodes are associated with increased dementia risk compared to single episodes 6
• VZV reactivation represents a modifiable risk factor for dementia, with vaccination showing protective effects 6

Infection Control Protocols

Critical distinction for isolation precautions:

• VZV infections (both varicella and disseminated zoster) require airborne and contact isolation in healthcare settings to prevent nosocomial transmission 8
• HSV-1/2 infections do not require airborne precautions 8
• Accurate viral identification through triplex NAAT testing (HSV-1/HSV-2/VZV) is essential when clinical diagnosis is uncertain 8

Common Pitfalls to Avoid

• Do not rely solely on clinical appearance to differentiate HSV from VZV—use molecular testing when diagnosis impacts isolation requirements 8
• Do not assume history of varicella is reliable in the vaccine era—only 75% of unimmunized children aged 1-4 years with positive varicella history are actually seropositive 1
• Do not use standard HSV dosing for VZV—treatment regimens, antiviral dosages, and duration vary significantly among HSV-1, HSV-2, and VZV 8
• Do not delay intravenous acyclovir in immunocompromised patients—VZV infections can be life-threatening in this population 5

Emerging Resistance Considerations

• Acyclovir-resistant, TK-deficient VZV mutants may emerge during treatment 5
• Foscarnet is the alternative when TK-deficient mutants develop, as it does not require viral TK for activity 5
• Acyclic nucleoside phosphonates (HPMPC) also remain effective against TK-deficient strains 5